Related references
Note: Only part of the references are listed.Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
Stephen Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?
G. Bianchini et al.
ANNALS OF ONCOLOGY (2008)
HER-2 and topoisomerase II as predictors of response to chemotherapy
Kathleen I. Pritchard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anthracycline cardiotoxicity: From bench to bedside
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel:: Breast International Group 02-98 randomized trial
Prudence Francis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Miguel Martin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Weekly paclitaxel in the adjuvant treatment of breast cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
Stephen E. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer
Christopher J. Poole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
L Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
MN Levine et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Adjuvant docetaxel for node-positive breast cancer
M Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer:: 10-year follow-up results of The French Adjuvant Study Group 05 randomized trial
J Bonneterre et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Statistical considerations in the intent-to-treat principle
JM Lachin
CONTROLLED CLINICAL TRIALS (2000)
Share Paper
